Cargando…

The Potential Effects of Curcumin on Pulmonary Fibroblasts of Idiopathic Pulmonary Fibrosis (IPF)—Approaching with Next-Generation Sequencing and Bioinformatics

Idiopathic pulmonary fibrosis (IPF) is a chronic and progressive interstitial lung disease. Currently, therapeutic options are limited for this fatal disease. Curcumin, with its pleiotropic effects, has been studied for its potential therapeutic utilities in various diseases, including pulmonary fib...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chang, Wei-An, Chen, Chia-Min, Sheu, Chau-Chyun, Liao, Ssu-Hui, Hsu, Ya-Ling, Tsai, Ming-Ju, Kuo, Po-Lin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7700625/ https://www.ncbi.nlm.nih.gov/pubmed/33233354 http://dx.doi.org/10.3390/molecules25225458

Ejemplares similares

The Effects of Epigallocatechin Gallate (EGCG) on Pulmonary Fibroblasts of Idiopathic Pulmonary Fibrosis (IPF)—A Next-Generation Sequencing and Bioinformatic Approach
por: Tsai, Ming-Ju, et al.
Publicado: (2019)

Bioinformatic analysis of next-generation sequencing data to identify dysregulated genes in fibroblasts of idiopathic pulmonary fibrosis
por: Sheu, Chau-Chyun, et al.
Publicado: (2019)

Gene Expression Changes Associated with Nintedanib Treatment in Idiopathic Pulmonary Fibrosis Fibroblasts: A Next-Generation Sequencing and Bioinformatics Study
por: Sheu, Chau-Chyun, et al.
Publicado: (2019)

IPF - Idiopathic Pulmonary Fibrosis
Publicado: (2019)

Idiopathic Pulmonary Fibrosis (IPF): An Overview
por: Barratt, Shaney L., et al.
Publicado: (2018)

Deducting MicroRNA-Mediated Changes Common in Bronchial Epithelial Cells of Asthma and Chronic Obstructive Pulmonary Disease—A Next-Generation Sequencing-Guided Bioinformatic Approach
por: Tsai, Ming-Ju, et al.
Publicado: (2019)

Colitis Associated with Nintedanib Therapy for Idiopathic Pulmonary Fibrosis (IPF)
por: Oda, Keishi, et al.
Publicado: (2017)

Time to diagnosis of idiopathic pulmonary fibrosis in the IPF-PRO Registry
por: Snyder, Laurie D, et al.
Publicado: (2020)

MiR-608 overexpression in idiopathic pulmonary fibrosis (IPF)
por: Epstein Shochet, Gali, et al.
Publicado: (2021)

Systematic analysis of transcriptomic profiles of COPD airway epithelium using next-generation sequencing and bioinformatics
por: Chang, Wei-An, et al.
Publicado: (2018)

Demographics and survival of patients with idiopathic pulmonary fibrosis in the FinnishIPF registry
por: Kaunisto, Jaana, et al.
Publicado: (2019)

Clinical characteristics of patients with familial idiopathic pulmonary fibrosis (f-IPF)
por: Krauss, Ekaterina, et al.
Publicado: (2019)

Fibroblast paracrine TNF-α signaling elevates integrin A5 expression in idiopathic pulmonary fibrosis (IPF)
por: Epstein Shochet, Gali, et al.
Publicado: (2017)

Rationale for and design of the Idiopathic Pulmonary Fibrosis–PRospective Outcomes (IPF-PRO) registry
por: O'Brien, Emily C, et al.
Publicado: (2016)

Management of patients with idiopathic pulmonary fibrosis in clinical practice: the INSIGHTS-IPF registry
por: Behr, Jürgen, et al.
Publicado: (2015)

Idiopathic Pulmonary Fibrosis in Elderly Patients: Analysis of the INSIGHTS-IPF Observational Study
por: Leuschner, Gabriela, et al.
Publicado: (2020)

Efficacy of antifibrotic drugs, nintedanib and pirfenidone, in treatment of progressive pulmonary fibrosis in both idiopathic pulmonary fibrosis (IPF) and non-IPF: a systematic review and meta-analysis
por: Finnerty, James Patrick, et al.
Publicado: (2021)

mTORC1 activation decreases autophagy in aging and idiopathic pulmonary fibrosis and contributes to apoptosis resistance in IPF fibroblasts
por: Romero, Yair, et al.
Publicado: (2016)

αAzithromycin has enhanced effects on lung fibroblasts from idiopathic pulmonary fibrosis (IPF) patients compared to controls
por: Krempaska, Kristina, et al.
Publicado: (2020)

Correction to: Azithromycin has enhanced effects on lung fibroblasts from idiopathic pulmonary fibrosis (IPF) patients compared to controls
por: Krempaska, Kristina, et al.
Publicado: (2020)

The transition from normal lung anatomy to minimal and established fibrosis in idiopathic pulmonary fibrosis (IPF)
por: Xu, Feng, et al.
Publicado: (2021)

Identification of novel genetic regulations associated with airway epithelial homeostasis using next-generation sequencing data and bioinformatics approaches
por: Sheu, Chau-Chyun, et al.
Publicado: (2017)

HSP90 Inhibition and Modulation of the Proteome: Therapeutical Implications for Idiopathic Pulmonary Fibrosis (IPF)
por: Colunga Biancatelli, Ruben Manuel Luciano, et al.
Publicado: (2020)

Serum Procalcitonin in Patients With Combined Lung Cancer and Idiopathic Pulmonary Fibrosis (LC-IPF)
por: Mohamed, Sherif, et al.
Publicado: (2020)

Clinical Outcomes of Patients with Combined Idiopathic Pulmonary Fibrosis and Emphysema in the IPF-PRO Registry
por: Kim, Hyun J., et al.
Publicado: (2022)

Regeneration or Repair? The Role of Alveolar Epithelial Cells in the Pathogenesis of Idiopathic Pulmonary Fibrosis (IPF)
por: Confalonieri, Paola, et al.
Publicado: (2022)

Pulmonary (18)F-FDG uptake helps refine current risk stratification in idiopathic pulmonary fibrosis (IPF)
por: Win, Thida, et al.
Publicado: (2018)

TGF-β pathway activation by idiopathic pulmonary fibrosis (IPF) fibroblast derived soluble factors is mediated by IL-6 trans-signaling
por: Epstein Shochet, Gali, et al.
Publicado: (2020)

Molecular Phenotypes Distinguish Patients with Relatively Stable from Progressive Idiopathic Pulmonary Fibrosis (IPF)
por: Boon, Kathy, et al.
Publicado: (2009)

Idiopathic pulmonary fibrosis in Sweden: report from the first year of activity of the Swedish IPF-Registry
por: Ferrara, Giovanni, et al.
Publicado: (2016)

IPF Care: A Support Program for Patients with Idiopathic Pulmonary Fibrosis Treated with Pirfenidone in Europe
por: Duck, Annette, et al.
Publicado: (2015)

The European IPF registry (eurIPFreg): baseline characteristics and survival of patients with idiopathic pulmonary fibrosis
por: Guenther, Andreas, et al.
Publicado: (2018)

Management and attitudes about IPF (Idiopathic Pulmonary Fibrosis) among physicians from Latin America
por: Cherrez-Ojeda, Iván, et al.
Publicado: (2018)

Differing severities of acute exacerbations of idiopathic pulmonary fibrosis (IPF): insights from the INPULSIS® trials
por: Kreuter, Michael, et al.
Publicado: (2019)

Antifibrotic Drug Use in Patients with Idiopathic Pulmonary Fibrosis. Data from the IPF-PRO Registry
por: Salisbury, Margaret L., et al.
Publicado: (2020)

Peripheral blood proteomic profiling of idiopathic pulmonary fibrosis biomarkers in the multicentre IPF-PRO Registry
por: Todd, Jamie L., et al.
Publicado: (2019)

There is detectable variation in the lipidomic profile between stable and progressive patients with idiopathic pulmonary fibrosis (IPF)
por: Nambiar, Shabarinath, et al.
Publicado: (2021)

Disparities in Lung Transplant among Patients with Idiopathic Pulmonary Fibrosis: An Analysis of the IPF-PRO Registry
por: Swaminathan, Aparna C., et al.
Publicado: (2022)

Radiological Assessment in Idiopathic Pulmonary Fibrosis (IPF) Patients According to MUC5B Polymorphism
por: Cocconcelli, Elisabetta, et al.
Publicado: (2022)

NICEFIT—A Prospective, Non-Interventional, and Multicentric Study for the Management of Idiopathic Pulmonary Fibrosis with Antifibrotic Therapy in Taiwan
por: Cheng, Shih-Lung, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_dnv836s4uiikomcj1pv004ko6d